Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Abstract Background Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) treatment, but is poorly tolerated or contraindicated in some patients. There is a wealth of data supporting the use of abatacept in combination with MTX, but data on alternative conventional synthetic diseas...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Rieke Alten, Harald Burkhardt, Eugen Feist, Klaus Krüger, Juergen Rech, Andrea Rubbert-Roth, Reinhard E. Voll, Yedid Elbez, Christiane Rauch
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2018-01-01
סדרה:	Arthritis Research & Therapy
נושאים:	Abatacept Conventional synthetic disease-modifying antirheumatic drug Azathioprine Hydroxychloroquine Leflunomide Methotrexate
גישה מקוונת:	http://link.springer.com/article/10.1186/s13075-017-1488-5
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!